狄诺塞麦对骨转移有多大的疗效？

How effective is it against bone metastasis? FREEDOM, a 3-year randomized, double-blind, placebo-controlled phase III clinical trial, evaluated the efficacy and safety of denosumab in the treatment of osteoporosis in postmenopausal women. Patients were randomized to treatment (denosumab 60 mg subcutaneously every 6 months, n=3902) or placebo (n=3906). The primary outcome measure was the incidence of new vertebral fractures over the 3-year period, and secondary outcomes included the incidence of hip and nonvertebral fractures and the time to first fracture during the observation period. The subjects were aged between 60 and 90 years old, with an average age of 72.3 years. The basic T-score value of the spine or total hip was between -4.0 and -2.5 (the average was -2.8). About 23% of the subjects had a history of at least one fracture before entering this trial. All patients also received daily supplements of 1000 mg of vegetarian calcium and 400 to 800 IU of vitamin D.

The results showed that compared with the placebo group, the incidence of new vertebral fractures in the treatment group was reduced by 68% (2.3% in the treatment group and 7.2% in the placebo group, P<0.0001), the incidence of hip fractures was reduced by 40% (0.7% in the treatment group and 1.2% in the placebo group, P=0.036), and the incidence of non-vertebral fractures was reduced by 20% (6.5% in the treatment group). , 8.0% in the placebo group, P =0.011).

It is a humanized IgG2 monoclonal antibody produced in mammalian cells through genetic engineering. The molecular formula is C6404 H9908 N1724 O2004 S50. Denosumab is currently on the market in many countries. Among them, denosumab on the market in Turkey is very cost-effective. You can travel with your own medicine for details.